Stryker stock falls 1.64 percent before October 29 results

Published on 10/06/2026 at 18:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stryker stock traded at USD 280.55 on October 6, 2026, down 1.64 percent during the session. Q2 adjusted EPS reached USD 3.69, above consensus by USD 0.20.

Isometrische Illustration der Wertschöpfungskette von Rohstoff bis Operationssaal — Isometrische 3D-Grafik zeigt die Wertschöpfungskette der Medizintechnik-Branche, in der Stryker Corp. US8636671013 tätig ist, Illustration mit AI erstellt.

Stryker Corporation (ISIN US8636671013) traded at USD 280.55 on the NYSE at 12:01 p.m. ET on October 6, 2026, down 1.64 percent during the session. The next scheduled test is the company's third-quarter report on October 29, 2026, when Stryker will discuss results in a 4:30 p.m. ET webcast, according to Markets Insider on October 1, 2026. The timing puts execution and recovery trends at the center of the next market reaction.

October 29 sets the next test

The October 29 release will cover the third quarter of fiscal 2026, with the financial statement scheduled for about 4:05 p.m. ET and the webcast 25 minutes later, according to Markets Insider.

That date matters because Stryker's second-quarter performance cleared expectations, while analysts have focused on growth in the second half of the year and the company's ability to manage operational disruptions.

Second quarter beat expectations

For the second quarter of 2026, Stryker reported adjusted earnings of USD 3.69 per share and revenue of USD 6.6 billion, according to Investing.com on September 9, 2026. Adjusted EPS exceeded the USD 3.49 consensus by USD 0.20, while revenue was above the USD 6.58 billion estimate and organic revenue growth reached 9 percent.

The same report said Stryker raised the low end of its fiscal 2026 organic growth guidance by 30 basis points and lifted its earnings guidance by USD 0.05. Wells Fargo nevertheless cut its price target to USD 348 from USD 418 while maintaining an Overweight rating, citing lower revenue assumptions and pressure in peripheral vascular products, hips and knees.

Consensus stays above the quote

MarketBeat lists a Moderate Buy consensus based on 19 Buy ratings and five Holds, with an average price target of USD 372.64, according to MarketBeat on October 3, 2026. That target lies 32.8 percent above the USD 280.55 price, leaving the consensus materially more optimistic than the current quotation.

Stryker stock trades below yearly high

At USD 280.55, Stryker stock was 28.6 percent below its 52-week high of USD 392.55 and USD 13.55 above its 52-week low of USD 267.00 on October 6, 2026. Market capitalization stood at USD 107.6 billion, with volume at 1,096,597 shares.